[go: up one dir, main page]

NO20021230L - Factor Xa inhibitors - Google Patents

Factor Xa inhibitors

Info

Publication number
NO20021230L
NO20021230L NO20021230A NO20021230A NO20021230L NO 20021230 L NO20021230 L NO 20021230L NO 20021230 A NO20021230 A NO 20021230A NO 20021230 A NO20021230 A NO 20021230A NO 20021230 L NO20021230 L NO 20021230L
Authority
NO
Norway
Prior art keywords
inhibitors
factor
Prior art date
Application number
NO20021230A
Other languages
Norwegian (no)
Other versions
NO20021230D0 (en
Inventor
Bing-Yan Zhu
Zhaozhong Jon Jia
Wenrong Huang
Yonghong Song
James Kanter
Robert M Scarborough
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NO20021230D0 publication Critical patent/NO20021230D0/en
Publication of NO20021230L publication Critical patent/NO20021230L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dot-Matrix Printers And Others (AREA)
  • Facsimile Image Signal Circuits (AREA)
  • Controls And Circuits For Display Device (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20021230A 1999-09-17 2002-03-12 Factor Xa inhibitors NO20021230L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15433299P 1999-09-17 1999-09-17
PCT/US2000/025195 WO2001019798A2 (en) 1999-09-17 2000-09-15 INHIBITORS OF FACTOR Xa

Publications (2)

Publication Number Publication Date
NO20021230D0 NO20021230D0 (en) 2002-03-12
NO20021230L true NO20021230L (en) 2002-05-21

Family

ID=22550934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021230A NO20021230L (en) 1999-09-17 2002-03-12 Factor Xa inhibitors

Country Status (16)

Country Link
EP (1) EP1216231A2 (en)
JP (1) JP2003509412A (en)
CN (1) CN1390206A (en)
AU (1) AU781880B2 (en)
BR (1) BR0014078A (en)
CA (1) CA2385589A1 (en)
CZ (1) CZ2002959A3 (en)
HU (1) HUP0203954A2 (en)
IL (1) IL148698A0 (en)
MX (1) MX228790B (en)
NO (1) NO20021230L (en)
NZ (1) NZ517828A (en)
RU (1) RU2002110295A (en)
TR (1) TR200201413T2 (en)
WO (1) WO2001019798A2 (en)
ZA (4) ZA200202116B (en)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142959A0 (en) 1998-12-23 2002-04-21 Du Pont Pharm Co Nitrogen containing heterobicycles as factor xa inhibitors
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2002010154A2 (en) 2000-07-27 2002-02-07 Eli Lilly And Company Substituted heterocyclic amides
DE60118774T2 (en) 2000-11-22 2007-03-15 Astellas Pharma Inc. SUBSTITUTED PHENOL DERIVATIVES AND THEIR SALTS AS INHIBITORS OF COAGULATION FACTOR X
EP1379506A2 (en) 2000-11-28 2004-01-14 Eli Lilly And Company Substituted carboxamides
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
CA2441772A1 (en) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
WO2002094197A2 (en) 2001-05-22 2002-11-28 Bristol-Myers Squibb Company Bicyclic inhibitors of factor xa
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
IL160693A0 (en) 2001-09-21 2004-08-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003050088A1 (en) 2001-12-07 2003-06-19 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
MXPA04012959A (en) * 2002-06-29 2005-05-16 Zentaris Gmbh Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases.
JP2005538118A (en) 2002-08-06 2005-12-15 アストラゼネカ アクチボラグ Condensed pyridine and pyrimidine with TIE2 (TEK) activity
ATE363470T1 (en) 2002-11-18 2007-06-15 Chemocentryx Inc ARYLSULFONAMIDE
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
EP1433788A1 (en) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
CA2511321A1 (en) * 2002-12-23 2004-07-08 Aventis Pharma Deutschland Gmbh Pyrazole-derivatives as factor xa inhibitors
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
EP1591443B1 (en) 2003-02-07 2010-08-25 Daiichi Sankyo Company, Limited Pyrazole derivative
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1620405A2 (en) * 2003-05-01 2006-02-01 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US7432281B2 (en) 2003-10-07 2008-10-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2005061463A1 (en) 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
WO2005090313A1 (en) 2004-03-18 2005-09-29 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (en) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Methods for treating hepatitis c.
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
EP1773781A2 (en) 2004-08-03 2007-04-18 Wyeth Indazoles useful in treating cardiovascular diseases
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003325A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
CN101083993A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as therapeutic agents
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101084212A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
RU2374234C2 (en) 2004-09-24 2009-11-27 Астразенека Аб Benzimidazole derivatives, compositions containing said derivatives, production and use thereof
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CA2593993C (en) 2004-12-30 2014-07-29 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
JP5184891B2 (en) 2005-01-07 2013-04-17 シンタ ファーマシューティカルズ コーポレーション Compounds used for inflammation and immunity related applications
ES2552338T3 (en) 2005-01-21 2015-11-27 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
CN101146532B (en) 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 Pharmaceutical compounds
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
MX2007011105A (en) 2005-03-10 2007-10-08 Pfizer Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds.
BRPI0611187A2 (en) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
JP2008546751A (en) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド Pharmaceutical composition
JP5345842B2 (en) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド Pharmaceutical combinations containing pyrazole derivatives as protein kinase modulators
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
JP2010509392A (en) 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
BRPI0809655B8 (en) * 2007-04-13 2021-05-25 Millennium Pharm Inc use of a compound and a therapeutic agent, pharmaceutical composition, and kit
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP3130674B1 (en) 2008-11-03 2020-07-08 ADC Therapeutics SA Antibodies that specifically block the biological activity of a tumor antigen
CN108524505A (en) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 Method and composition for cell Proliferation associated disease
JP5756457B2 (en) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
BRPI1010024A2 (en) 2009-06-05 2019-09-24 Link Medicine Corp aminopyrrolidinone derivatives and their use
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
BR112012010752B1 (en) 2009-11-05 2021-07-20 University Of Notre Dame Du Lac IMIDAZO[1,2-A]PYRIDINE COMPOUNDS
KR101955691B1 (en) 2010-03-30 2019-03-07 베르선 코포레이션 Multisubstituted aromatic compounds as inhibitors of thrombin
CN101870636B (en) * 2010-04-01 2013-01-23 大唐(杭州)医药化工有限公司 Preparation method of 2-bromo-6-fluoronaphthalene
JP5837091B2 (en) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ， インコーポレイテッド Novel N- (4- (azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as modulators of pyruvate kinase M2 (PKM2)
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
SMT201900505T1 (en) 2011-03-31 2019-11-13 Adc Therapeutics Sa Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
CA2834692A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
PT2704721T (en) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
CN111298119A (en) 2012-01-09 2020-06-19 Adc治疗股份有限公司 Methods for treating triple negative breast cancer and basal-like breast cancer by using inhibitors of kidney associated antigen 1(KAAG1)
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN103483242A (en) * 2012-06-15 2014-01-01 上海朴颐化学科技有限公司 Preparation methods of 4-(2'-pyridyl)benzyl hydrazine and its intermediate
US9163021B2 (en) 2012-10-04 2015-10-20 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
RU2015144193A (en) 2013-03-15 2017-04-24 Версеон Корпорейшн HALOGENPYRAZOLES AS THROMBINE INHIBITORS
BR112015022340A2 (en) 2013-03-15 2017-07-18 Verseon Corp method for treating or preventing a kallikrein-related disease or disorder in a subject, compound, and pharmaceutical composition
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
KR102430607B1 (en) * 2014-06-11 2022-08-08 바이엘 크롭사이언스 악티엔게젤샤프트 Process for preparing 3,5-bis(haloalkyl)pyrazoles via acylation of ketimines
CN104016944B (en) * 2014-06-16 2016-05-18 山东大学 N-(2-(amine methyl) phenyl) thiazole-4-carboxamide derivative and preparation method thereof and application
MX2017003624A (en) 2014-09-17 2017-07-13 Verseon Corp Pyrazolyl-substituted pyridone compounds as serine protease inhibitors.
JP2018506563A (en) 2015-02-27 2018-03-08 ヴァーセオン コーポレイション Substituted pyrazole compounds as serine protease inhibitors
RS64777B1 (en) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Methods of using pyruvate kinase activators
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2017049321A1 (en) 2015-09-17 2017-03-23 Miller Marvin J Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
FI3362065T3 (en) 2015-10-15 2024-06-19 Servier Lab Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
HRP20211790T1 (en) 2015-10-15 2022-03-04 Les Laboratoires Servier Combination therapy for treating malignancies
KR102717600B1 (en) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. Inhibition of ubiquitin-specific peptidase 30
BR112020016466A2 (en) 2018-02-13 2020-12-15 Gilead Sciences, Inc. COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO INHIBIT PD-1, PD-L1 AND / OR THE INTERACTION OF PD-1 / PD-L1, TO TREAT CANCER AND TO IMPROVE T-CELL FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS (CHB) , AND, KIT TO TREAT OR PREVENT CANCER OR A DISEASE OR CONDITION.
ES3035911T3 (en) 2018-04-19 2025-09-11 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
PE20201202A1 (en) 2018-04-26 2020-11-11 Pfizer CYCLINE-DEPENDENT KINASE INHIBITORS
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CA3110113A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
JP7158577B2 (en) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド PD-1/PD-L1 inhibitor
HUE059638T2 (en) 2019-05-10 2022-12-28 Synact Pharma Aps Combined treatment of inflammatory joint diseases
MD3986890T3 (en) 2019-06-18 2025-07-31 Pfizer Benzisoxazole sulfonamide derivatives
UA130303C2 (en) 2019-12-06 2026-01-14 Вертекс Фармасьютикалз Інкорпорейтед SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
MX2023014378A (en) 2021-06-04 2023-12-15 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels.
KR20240024177A (en) 2021-06-21 2024-02-23 신액트 파마 에이피에스 Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946508B1 (en) * 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP0946528B1 (en) * 1996-12-23 2003-04-09 Bristol-Myers Squibb Pharma Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP0993448A1 (en) * 1997-06-19 2000-04-19 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS

Also Published As

Publication number Publication date
WO2001019798A3 (en) 2001-10-25
RU2002110295A (en) 2003-12-10
EP1216231A2 (en) 2002-06-26
NZ517828A (en) 2003-10-31
BR0014078A (en) 2002-12-31
CZ2002959A3 (en) 2002-07-17
ZA200202116B (en) 2004-02-10
NO20021230D0 (en) 2002-03-12
AU781880B2 (en) 2005-06-16
TR200201413T2 (en) 2003-02-21
CA2385589A1 (en) 2001-03-22
ZA200306490B (en) 2004-05-26
HUP0203954A2 (en) 2003-03-28
WO2001019798A2 (en) 2001-03-22
JP2003509412A (en) 2003-03-11
IL148698A0 (en) 2002-09-12
MXPA02002762A (en) 2003-10-14
MX228790B (en) 2005-06-30
CN1390206A (en) 2003-01-08
AU7486600A (en) 2001-04-17
ZA200202117B (en) 2004-02-25
ZA200306488B (en) 2004-04-28

Similar Documents

Publication Publication Date Title
NO20021230L (en) Factor Xa inhibitors
ATE346050T1 (en) SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR XA INHIBITORS
NO20013072D0 (en) Nitrogen-containing heterocycles as factor Xa inhibitors
ATE243681T1 (en) BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS
NO20042592L (en) Indole-2-carboxamides as factor XA inhibitors
NO20011293D0 (en) Factor VIIa inhibitors
DE69829879D1 (en) INDOLE DERIVATIVES AS FACTOR XA INHIBITORS
PT1181017E (en) METALOPROTEASE INHIBITORS
DE60020259D1 (en) C-ARYL-glucoside SGLT2 INHIBITORS
AU2002350217A8 (en) Glycinamides as factor xa inhibitors
PT1194404E (en) ASPARTIL-PROTEASE INHIBITORS
NO20042990L (en) Pyrrolidin-2-ones as factor XA inhibitors
ATE289294T1 (en) PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS
DE10082488T1 (en) Storage unit
ATE246707T1 (en) FACTOR VIIA INHIBITORS
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
ATE309824T1 (en) ENZYMIN HIBITORS
ATE305452T1 (en) FACTOR XA INHIBITOR
DE50001156D1 (en) holder
DE50005136D1 (en) holder
DK199901689A (en) Coating
FI991190L (en) I rotated
FI990150A0 (en) Holder
NO995747D0 (en) Holder
SE9900370D0 (en) Holder

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application